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Abstract
Objectives—Adoption of human papillomavirus (HPV) vaccination in the US has been slow. In
2011, HPV vaccination of boys was recommended by CDC for routine use at ages 11–12. We
conducted and evaluated a social marketing intervention with parents and providers to stimulate
HPV vaccination among preteen boys.
Methods—We targeted parents and providers of 9–13 year old boys in a 13 county NC region.
The 3-month intervention included distribution of HPV vaccination posters and brochures to all
county health departments plus 194 enrolled providers; two radio PSAs; and an online CME
training. A Cox proportional hazards model was fit using NC immunization registry data to
examine whether vaccination rates in 9–13 year old boys increased during the intervention period
in targeted counties compared to control counties (n=15) with similar demographics. To compare
with other adolescent vaccines, similar models were fit for HPV vaccination in girls and
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meningococcal and Tdap vaccination of boys in the same age range. Moderating effects of age,
race, and Vaccines for Children (VFC) eligibility on the intervention were considered.
Results—The Cox model showed an intervention effect (β=0.29, HR=1.34, p=.0024), indicating
that during the intervention the probability of vaccination increased by 34% in the intervention
counties relative to the control counties. Comparisons with HPV vaccination in girls and Tdap and
meningococcal vaccination in boys suggest a unique boost for HPV vaccination in boys during the
intervention. Model covariates of age, race and VFC eligibility were all significantly associated
with vaccination rates (p<.0001 for all). HPV vaccination rates were highest in the 11–12 year old
boys. Overall, three of every four clinic visits for Tdap and meningococcal vaccines for preteen
boys were missed opportunities to administer HPV vaccination simultaneously.
Conclusions—Social marketing techniques can encourage parents and health care providers to
vaccinate preteen boys against HPV.
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HPV vaccine; social marketing; preteen boys; adolescent immunization
1. Introduction
Public health interventions often take years to be broadly adopted and sustained in practice
settings,[1] and the human papillomavirus (HPV) vaccine is no exception.[2, 3] Two
vaccines have been approved by the Food and Drug Administration (FDA) for use in the
United States: HPV2, which protects against two types (16 and 18) of the virus, and HPV4,
which protects against four types (6, 11, 16, 18). HPV types 6 and 11 cause genital warts
and types 16 and 18 are associated with cervical, vaginal, vulvar, anal, penile, and throat
cancers. [4, 5] Initial studies of vaccine effectiveness in reducing HPV infection and disease
are promising.[4, 6]
Vaccination against HPV is most effective when given before sexual exposure to the virus.
[7, 8] The Centers for Disease Control and Prevention (CDC)'s Advisory Committee on
Immunization Practices (ACIP) first recommended HPV4 vaccination for routine clinical
use in females, ages 11–12, in 2006[7] and in males, ages 11–12, in 2011.[8] HPV4 vaccine
is the only one licensed for males. However, adoption of the vaccine has been slower than
expected.[2] At the end of 2012, completion of the 3-dose HPV4 vaccine series among
females and males ages 13–17 in the US was only 33% and 7% respectively.[2] By contrast,
coverage estimates among teens aged 13–15 years for ≥1 Tdap vaccine dose and ≥1
meningococcal vaccine dose were 85% and 74%, respectively, indicating that the Healthy
People 2020 goal of 80% vaccination coverage for adolescent vaccines is achievable.[2, 9]
This lag in HPV vaccination coverage exists in spite of ACIP's recommendation that all age-
appropriate vaccines be administered at a single visit.[2]
HPV vaccine has been primarily marketed to females to protect against cervical cancer.[10]
Yet, HPV vaccination of boys would prevent most of an estimated 7,490 cases of HPV-
associated cancer cases diagnosed annually in males.[6, 11, 12] A significant barrier to
HPV-vaccination among preteens is reluctance by both healthcare providers and parents to
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vaccinate at a young age.[2, 11, 13, 14] Health care providers play an influential role in
parents' decisions to vaccinate their sons against HPV, yet evidence suggests providers are
not yet fully promoting the vaccine at the recommended ages of 11–12.[2, 13–16] Lack of
parental awareness coupled with underutilization of the vaccine lead to missed opportunities
to reduce HPV disease and associated cancers.[2, 14, 17, 18]
The objective of our study was to conduct and evaluate a social marketing intervention with
parents and providers to stimulate HPV vaccination among preteen boys at a critical time
when the vaccine was new to both parents and clinical practice.
2. Methods
We evaluated a set of social marketing strategies intended to promote HPV vaccination in
preteen boys, especially among racial and ethnic populations at greater risk of disease. We
report here county-level vaccination data from the North Carolina Immunization Registry
(NCIR) to assess outcome effects from the intervention. We also compared self-reported pre
and post intervention vaccine knowledge, attitudes, beliefs, intentions and behaviors in
parents and providers in intervention counties; and assessed campaign exposure and recall
by parents and use of campaign materials by providers. Findings from these surveys are
reported elsewhere.[19, 20]
2.1 Setting
We conducted an intervention to promote HPV vaccination with parents of preteen boys and
healthcare providers who serve them in a 13 county region in NC in June-September, 2012.
This region[21] includes relatively higher percentages of minority (non-Caucasian) groups
than those for the state (Black/African American, 31.3% vs. 24.3%; American Indian, 8.0%
vs. 1.2%; Hispanic/Latino, 10.4% vs 9.8%).[22] These racial and ethnic groups have higher
reported rates of sexually transmitted infections and cancer-related consequences than do
whites. [23]
2.2. Intervention description
Within the first year after the HPV4 vaccine was routinely recommended for males, ages
11–12, we tested a set of social marketing strategies to motivate parents of preteen boys to
initiate HPV vaccinations and providers to start the vaccine series at the recommended ages
of 11–12. Social marketing is the use of persuasive principles to influence human behavior
in order to improve health or benefit society.[24] We based the intervention on four
principles of social marketing:[24, 25] to promote (with radio public service announcements,
posters, brochures, doctor's recommendation) the product (HPV vaccine), while considering
the price (cost, perception of safety and efficacy, and access), and place (healthcare
providers' office). Intervention counties were exposed to a campaign (Protect Him) with
materials designed and pretested with racially and ethnically diverse parents of preteen boys,
while control counties received no intervention.[26] The campaign ran for three months
before the school year started and when parents were most likely to seek vaccinations for
their children.
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Key features of the intervention were based on our formative research[26] with parents and
providers in the region and included:
• Two public service announcements designed to raise awareness about HPV vaccine
for boys; ads ran for eight weeks with seven radio stations targeting parents of
preteen boys in the 13 counties.
• Posters and brochures in English and Spanish (25,000 distributed to enrolled
providers and 13 health departments) with the risk-related message, “One in two
people will get HPV, which can lead to genital warts and cancer,” and multi-
cultural images of parents and sons close together;
• One hour CME webinar with video vignettes modeling communication among
providers, parents and preteen boys available to enrolled providers at no charge;
• One page tip sheet for providers to discuss HPV vaccination with parents and boys;
• Website (protecthim.org) with links to credible information sources, (e.g. CDC,
pediatric and family medicine associations), useful for both parents and providers.
Additional description of the intervention and findings from the pre and post intervention
surveys with parents and providers are reported in a second paper.
2.3. Study design
To measure the immunization impact of the intervention, we examined data from the NCIR,
a population based Web application containing consolidated demographic and immunization
history information on all of the recommended and required vaccines for NC citizens of all
ages.[27] NCIR includes data reported regularly by NC healthcare practices by age, race/
ethnicity and eligibility for Vaccines for Children (VFC), which provides vaccines
recommended by ACIP and for children who might not be able to pay.[27] We compared
HPV vaccine uptake (initial dose) in 13 intervention counties with a control group of 15
counties with socioeconomic characteristics similar to the intervention region.[21] To
minimize possible contamination effects from intervention activities that may stimulate
HPV vaccination among preteen males in a comparison group, we selected a control group
of northeastern NC counties that was geographically distant and in a different radio market
from the intervention region. We compared HPV vaccination in preteen males with HPV
vaccination in preteen females and with two other adolescent age vaccines, Tdap and
meningococcal. The Tdap vaccine is required for NC school entry in sixth grade while the
meningococcal vaccine is voluntary.[27] To place these comparisons in context, we also
examined vaccine uptake in all 100 counties in NC.
2.4. Data collection and measures
We received cohort data from NCIR for all children in the registry who: 1) were 9–13 years
old at any time during the intervention (June 15-September 15, 2012), and 2) had any record
of receiving HPV, Tdap, or meningococcal vaccine during the 15 month study period.[22]At
baseline (6 months prior to the start of the intervention), we identified a risk set of males
who had not received the HPV vaccine and examined their vaccination records for the 6
month pre-intervention, 3 month intervention, and 6 month post-intervention periods. This
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cohort was analyzed to examine effectiveness of the intervention by comparing vaccination
rates in the 13 intervention counties and the group of 15 control counties.
2.5. Data analyses
We used survival[28] (event history) analysis methods to estimate the vaccination rate
before, during, and after the intervention. We expected a larger increase in HPV vaccination
rates in members of the cohort in the intervention counties than the control counties. We
computed the time-to-initiation of HPV series for members of the risk set. Boys who
remained unvaccinated (HPV vaccine initiation) six months post-intervention were treated
as having censored (incomplete) vaccination times. These data were examined descriptively
as initiation rates for each time range and in the form of Kaplan-Meier survival curves.
First, the intervention effect was examined using a Cox proportional hazards model for time-
to-initiation of HPV series for members of this risk set. The Cox model included a random
effect (frailty parameter) for county, allowing for the estimation of a separate baseline
vaccination rate in each county. The effect of the intervention was modeled using a time-
varying covariate which took the value 0 for all counties up until the start of the
intervention, then took the value 1 for intervention counties. An additional time-varying
covariate took the value 0 everywhere except in the intervention counties during the post-
intervention period. Tests of the parameters (model coefficients) corresponding to these
time-varying covariates will indicate the presence of intervention effects during the three-
month intervention and whether intervention effects were sustained in the six months
following the intervention.
Second, to demonstrate whether the intervention was successfully targeted to HPV
vaccination in boys, we fit similar models for HPV vaccination of girls and meningococcal
and Tdap vaccination of boys in the same age range.
Third, we explored whether the intervention effect was modified by the three demographic
variables (age, race/ethnicity, and VFC eligibility) in NCIR. Each potential effect modifier
was examined separately, first through the construction of Kaplan-Meier curves, and then by
adding interaction terms between the intervention status and the potential effect modifier to
the previously-described Cox model. To avoid small sample sizes, analysis of the effect of
race/ethnicity was limited to the three largest groups: Non-Hispanic White (NHW), Non-
Hispanic Black/AA, and Hispanic (any race).
Fourth, we examined the extent to which providers were administering the HPV vaccine
series in conjunction with one or more other vaccines. We defined “missed opportunity” for
HPV vaccination as a clinic visit when a boy received either of the other two adolescent
vaccines (Tdap or meningococcal) but not HPV. We computed the proportion of these
opportunities in which a boy aged 11–13 received the HPV vaccine for the intervention
counties, the control counties, and the state as a whole. The intervention and control counties
were compared using a chi-square test.
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3.1. Characteristics of sample
In the NCIR data, there were 176,590 boys at risk for HPV vaccination during the study
period, including 19,842 in the intervention and 6,027 in the control counties. Demographics
for the entire state, and by intervention group, are in Table 1.
Compared to the intervention counties, boys not yet vaccinated for HPV at baseline in the
control counties were slightly older (59.5% vs. 56.8% age 12–13, p<.0001). The control and
intervention counties also had different racial breakdowns (P<.0001), with the control
counties having fewer American Indian/Alaska Natives, fewer Hispanics, and more Non-
Hispanic Black/African American boys in the risk set.
3.2. Intervention effects on HPV vaccination
Table 1 includes the HPV vaccination initiation outcome for all boys in the analysis. The
data show the intervention group had a higher vaccination percentage during the
intervention than the control group and a lower percentage remaining unvaccinated at the
end of the study. Figure 1a–d shows the Kaplan-Meier curves corresponding to the data in
Table 1.
In Figure 1a, which shows the HPV vaccination rates in 9–13 year old boys, the solid black
line (intervention group) decreases more rapidly than the dashed black line (control group)
starting around the time of the intervention, and supports greater uptake of vaccination in the
intervention counties during that three months. The Cox proportional hazard model for HPV
initiation in boys (first row of Table 2) quantifies the intervention effects, controlling for
race, age, and VFC eligibility. During the intervention period, the effect of the intervention
was statistically significant (p=.002). There was a significantly larger increase in vaccination
rates in 9–13 year old boys in the intervention counties than the control counties. The hazard
ratio (HR) of 1.34 indicates that an unvaccinated boy in the risk set was 34% more likely to
get vaccinated during the three months in an intervention county than in a control county.
There is no evidence that this effect was sustained past the intervention period, which is
tested as the sum of the intervention effect and the post-intervention increment (HR=.99, p=.
87).
3.3. Intervention effects on other adolescent vaccines
Figure 1b–d and the remaining rows in Table 2 provide the results of the Cox model
assessing the intervention's effect on other adolescent vaccines. The intervention's effect on
meningococcal vaccination in boys and HPV vaccination in girls was not significant. Boys
in the NCIR data in the intervention counties were, however, 24% less likely to get a Tdap
booster during the intervention and 16% less likely to get a Tdap booster in the period after
the intervention (p<.001 and p=.02 respectively) than boys in the control counties.
3.4. Effect modification by age, race, and VFC eligibility
The demographic variables were each examined as potential modifiers of the intervention's
effect on HPV vaccination through the examination of Kaplan –Meier curves (Figure 2) and
Cates et al. Page 6






















by adding interaction terms to the Cox model (Table 3). There was a significant
modification of the intervention effect by age (p<.0001). The intervention effect was
significant in the 11–12 year-old group (HR=1.54, p<.0001), which had a 54% higher
probability of vaccination in the intervention vs. control counties, but not in the 9–10 year-
old group (HR=1.05, p=.72) or 13 year-old group (HR=1.09, p=.48) of boys.
The interaction between race and the intervention effect was marginally significant (p=.08).
Specifically, there was a significant intervention effect in NHWs (p=.004) and Non-Hispanic
Black/AAs (p=.002), corresponding to about a 40% increase in likelihood of vaccination in
the intervention relative to control counties for members of these groups. In contrast, the
intervention effect was not significant in Hispanics (HR=1.09, p=.54).
The intervention effect was significant in both the VFC eligible and ineligible boys, and did
not vary significantly according to VFC eligibility (HR=1.5 vs. 1.3, p=.11).
3.5. Missed opportunities
For missed opportunities, we compared the number of boys ages 11–13 receiving HPV
vaccination as a percentage of the number of total vaccination visits for the intervention and
control counties and for the entire state (Table 4a). Overall, three of every four clinic visits
included Tdap or meningococcal vaccination but not for HPV.
Table 4a also shows that for Tdap and meningococcal vaccinations, prior to the intervention,
there were slightly but non-significantly fewer missed opportunities in the intervention than
control counties (p=.07), but during the intervention period boys in the intervention counties
were significantly more likely to include the HPV vaccine with other vaccines than boys in
the control counties (29.6% vs. 18.8%, p<.0001). Inclusion of the HPV vaccine remained
higher in the intervention counties than the control counties in the six months post-
intervention (p=.01).
To control for the potential bias of Tdap being a mandatory vaccine to enter sixth grade, we
conducted an analysis of missed opportunities that excluded the required Tdap vaccine, thus
only including the meningococcal vaccine in the denominator. For meningococcal only, the
intervention and control counties are not significantly different pre-intervention, but the rate
of inclusion of the HPV vaccine is significantly higher in the intervention than the control
counties both during (p<.0001) and after (p=.02) the intervention (Table 4b).
4. Discussion
The “Protect Him” campaign was a social marketing intervention to increase HPV vaccine
uptake among 11–12 year old boys in a 13-county region in North Carolina. Our analyses of
the state's immunization registry data suggest a modest but significant intervention effect by
boosting HPV vaccination of preteen boys in the targeted counties. We found that an
unvaccinated boy in NCIR was 34% more likely to get vaccinated during the 12-week
campaign period in an intervention county than in a control county. Additional comparisons
between HPV vaccine uptake of preteen boys and HPV vaccine uptake of preteen girls
showed significantly greater uptake for boys during the intervention. Finally, comparisons
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between boys' vaccination with Tdap and meningococcal vaccines during the same time
period suggest a unique boost for HPV vaccinations. We examined age, race, and Vaccine
for Children eligibility status and found moderating effects by age and by race (intervention
was most effective in 11–12 year olds and in non-Hispanic whites and non-Hispanic Blacks/
African Americans) but not by VFC status. As far as we know, the current study is the first
to use a social marketing intervention to boost HPV vaccination among preteen males.[29]
These strategies may be successfully used to increase HPV vaccination and ultimately
reduce HPV infection in males,[30] but HPV vaccine uptake in boys, as in girls, still has a
long way to go to achieve the 80% completion rate envisioned in Healthy People 2020.
Effective evaluation of social marketing campaigns using mass media is complex and
usually involves multiple methods, including measures of both process and outcomes.[31,
32] Claims of intervention effect may be challenged by confounding influences, such as
competing campaigns or other outreach efforts. One way to test for possible confounders of
a quasi-experimental (population-based) intervention is to measure and compare similar, but
non-equivalent immunization data such as meningococcal and Tdap vaccination. This
method strengthens the evaluation of a campaign by incorporating measurement of multiple
dependent variables at multiple time points. [31] In this study, we measured the main
outcome variable of HPV vaccination of boys and three non-equivalent dependent variables
(HPV vaccination of girls and Tdap and meningococcal vaccination of boys) at points not
only during the intervention, but also prior to and following the intervention. We found that
boys in the intervention group were less likely to get the Tdap vaccine than boys in the
control group during the three months of the intervention. One possible reason for this,
according to NC Immunization Branch personnel, is that the control counties may have been
lagging behind in Tdap vaccinations, and the end of summer was a catch-up period for boys
in those counties before they went back to school.[33]
An important contribution of the present study is the empirical evidence collected and
analyzed to document missed opportunities to vaccinate preteens against HPV at clinic visits
when they are receiving other adolescent vaccines. Underutilization of the vaccine leads to
missed opportunities to reduce HPV disease and associated cancers in males.[2] Measuring
adolescent immunizations through vaccine registries may then be an additional way to
evaluate efforts to increase HPV vaccination uptake and completion.[34]
Our study has several limitations. To the best that we could ascertain, there were no other
campaigns urging preteen vaccination of males during the 12 week intervention in our
targeted counties.[33, 35] If so, this would affect our claim that this social marketing
intervention boosted HPV vaccination among preteen boys. There is also the possibility that
the control counties may have been exposed to messages from our campaign. Any
contamination would have reduced intervention effects; therefore it is possible that the
intervention effect may be greater than what we measured. However to minimize the
possibility of contamination, we used locally targeted radio stations, recruited providers and
distributed materials only to practices in the intervention region.
We measured county-level reports of vaccination status, an appropriate measurement
strategy for a population-based social media campaign Because the design is not
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randomized, we used other known techniques[36] to strengthen our claims to causality
including three non-equivalent dependent variables (Tdap, meningococcal, HPV vaccine for
girls) and before/after surveys with parents and providers to measure mediating/explanatory
variables. We analyzed self-reported data for intervention impact on individual knowledge,
attitudes, and HPV vaccine intentions and initiations by parents of boys ages 9–13 and their
providers for a second paper.
Another limitation is the exclusion of children who had no adolescent vaccinations during
the intervention period, which does not allow our estimates of vaccination rates to be
extrapolated to the population as a whole, though this limitation does not affect our analysis
of missed opportunities. In addition, cost analysis was beyond the scope of the study so we
did not assess per dose cost of the intervention. We are planning future research to include
cost analysis in evaluation of the intervention components.
5. Conclusion
The objective of our study was to conduct and measure a social marketing intervention with
parents and providers to stimulate HPV vaccination among preteen boys at a critical time
when the vaccine was new to both parents and clinical practice. We hypothesized that our
outreach would increase HPV vaccine uptake among preteen boys in intervention counties
compared to control counties. We recommend comparing adolescent immunization trends
on a county and regional level as an important mechanism for evaluating intervention
effects.
Acknowledgments
The authors would like to thank Amy Grimshaw, Beth Quinn and Amanda Dayton from NC DHHS, Immunization
Branch for facilitating NCIR data access and its interpretation, and the NC South Central Partnership for Public
Health for ongoing support and feedback.
Funding source: This study was supported by grants from the National Institutes of Health 1R21A1095590-01A1
(Cates PI), and by the North Carolina Translational and Clinical Sciences Institute, through support from the
National Center for Advancing Translational Sciences (NCATS), National Institutes of Health, Grant Award
Number 1UL1TR001111. The content is solely the responsibility of the authors and does not necessarily represent
the official views of the NIH.
References
[1]. Brownson RC, et al. Designing for Dissemination Among Public Health Researchers: Findings
From a National Survey in the United States. American Journal of Public Health. 2013; 103(9):
1693–1699. [PubMed: 23865659]
[2]. Centers for Disease Control and Prevention. National and State Vaccination Coverage Among
Adolescents Aged 13–17 Years - United States, 2012. Morbidity and Mortality Weekly Report.
2013; 62(34):685–693. [PubMed: 23985496]
[3]. National Cancer Institute. Accelerating HPV Vaccine Uptake: Urgency for Action to Prevent
Cancer. A Report to the President of the United States from the President's Cancer Panel. U.S.
Department of Health and Human Services, National Insitutes of Health; Bethesda, MD: 2014.
[4]. Markowitz LE, et al. Reduction in Human Papillomavirus (HPV) Prevalence Among Young
Women Following HPV Vaccine Introduction in the United States, National Health and Nutrition
Examination Surveys, 2003–2010. Journal of Infectious Diseases. 2013
[5]. National Cancer Institute. Fact Sheet - HPV and Cancer. 2012.
Cates et al. Page 9






















[6]. Hariri S, et al. Population Impact of HPV Vaccines: Summary of Early Evidence. The Journal of
adolescent health : official publication of the Society for Adolescent Medicine. 2013; 53(6):679–
682. [PubMed: 24263069]
[7]. Centers for Disease Control and Prevention. Recommended Immunization Schedules for Persons
Aged 0–18 years - United States, 2007. Morbidity and Mortality Weekly Report. 2007; 55(51 &
52):Q1–4.
[8]. Centers for Disease Control and Prevention. Recommendations on the Use of Quadrivalent Human
Papillomavirus Vaccine in Males — Advisory Committee on Immunization Practices (ACIP),
2011. Morbidity and Mortality Weekly Report. 2011; 60(50):1705–1708. [PubMed: 22189893]
[9]. U. S. Department of Health and Human Services. Healthy People 2020. Jun 21. 2013
2010Available from: http://healthypeople.gov/2020/topicsobjectives2020/objectiveslist.aspx?
topicId=23
[10]. Rothman SM, Rothman DJ. Marketing HPV Vaccine: Implications for Adolescent Health and
Medical Professionalism. JAMA. 2009; 302(7):781–786. [PubMed: 19690311]
[11]. Centers for Disease Control and Prevention. Human Papillomavirus Vaccination Coverage
Among Adolescent Girls, 2007–2012, and Postlicensure Vaccine Safety Monitoring, 2006–2013
— United States. Morbidity and Mortality Weekly Report. 2013; 62(29):591–595. [PubMed:
23884346]
[12]. Markowitz, L. HPV Vaccine for Males: Background and Review of Data. Advisory Committee
on Immunization Practices. , editor. Centers for Disease Control and Prevention; Atlanta, GA:
2011.
[13]. Vadaparampil ST, et al. Physicians' human papillomavirus vaccine recommendations, 2009 and
2011. Am J Prev Med. 2014; 46(1):80–4. [PubMed: 24355675]
[14]. Holman DM, et al. Barriers to human papillomavirus vaccination among us adolescents: A
systematic review of the literature. JAMA Pediatrics. 2013:E1–E7.
[15]. Healy CM, Montesinos DP, Middleman AB. Parent and provider perspectives on immunization:
Are providers overestimating parental concerns? Vaccine. 2014; 32(5):579–584. [PubMed:
24315883]
[16]. Mergler MJ, et al. Association of vaccine-related attitudes and beliefs between parents and health
care providers. Vaccine. 2013; 31(41):4591–4595. [PubMed: 23896424]
[17]. Vadaparampil ST, et al. Missed clinical opportunities: Provider recommendations for HPV
vaccination for 11–12 year old girls are limited. Vaccine. 2011; 29(47):8634–8641. [PubMed:
21924315]
[18]. Wisk LE, Allchin A, Witt WP. Disparities in Human Papillomavirus Vaccine Awareness Among
US Parents of Preadolescents and Adolescents. Sexually Transmitted Diseases. 2014; 41(2):117–
122. 10.1097/OLQ.0000000000000086. [PubMed: 24413492]
[19]. Cates, JR., et al. Optimizing HPV Vaccination for Boys: Opportunities for Enhanced
Communication. DC Health Communication Conference; George Mason University; 2013.
[20]. Cates, JR., et al. Encouraging HPV vaccination for preteen boys: Response to a social marketing
campaign. National Conference on Health Communication, Marketing, and Media; Atlanta, GA:
National Public Health Information Coalition; 2013.
[21]. North Carolina Institute for Public Health. NC Public Health Incubator Collaboratives. UNC-
Chapel Hill School of Public Health; Chapel Hill, NC: 2011.
[22]. North Carolina Immunization Branch. Immunize North Carolina: North Carolina Immunization
Registry. 2011.
[23]. Centers for Disease Control and Prevention. Sexually Transmitted Diseases in the United States,
2008: National Surveillance Data for Chlamydia, Gonorrhea, and Syphilis. 2008.
[24]. Andreasen, AR. Social Marketing in the 21st Century. Sage Publications; Thousand Oaks, CA:
2006.
[25]. Lefebvre, RC.; Rochlin, L. Social marketing. In: Glanz, K.; Lewis, FM.; Rimer, BK., editors.
Health behavior and health education: Theory, research, and practice. Jossey-Bass; San
Francisco: 1997. p. 384-402.
Cates et al. Page 10






















[26]. Cates JR, et al. Designing messages to motivate parents to get their preteenage sons vaccinated
against human papillomavirus. Perspectives in Sexual and Reproductive Health. 2012; 44(1):39–
47. PMID: 22405151.
[27]. North Carolina Immunization Branch. The North Carolina Immunization Registry (NCIR). 2014.
[cited 2014 February 20]; Available from: http://www.immunize.nc.gov/providers/ncir.htm
[28]. Anderson P. Multi-state models for event history analysis. Statistical Methods in Medical
Research. 2002; 11:91–115. [PubMed: 12040698]
[29]. Sadaf A, et al. A systematic review of interventions for reducing parental vaccine refusal and
vaccine hesitancy. Vaccine. 2013; 31(40):4293–4304. [PubMed: 23859839]
[30]. Cates, JR., et al. Communicating risk: Parents' and healthcare providers' response to a social
marketing intervention to promote HPV vaccination in preteen boys. University of North
Carolina; Chapel Hill, NC: 2014.
[31]. Hornik, RC. Epilogue: Evaluation design for public health communication programs. In: Hornik,
RC., editor. Public health communication: Evidence for behavior change (pp. 385–405).
Lawrence Erlbaum; Mahwah, NJ: 2002. p. 385-405.
[32]. Noar SM. A 10-year retrospective of research in health mass media campaigns: Where do we go
from here? Journal of Health Communication. 2006; 11(1):21–42. [PubMed: 16546917]
[33]. Quinn, B. Immunization Results from HPV Vaccination Social marketing Campaign in 2012.
Cates, J., editor. University of North Carolina at Chapel Hill; 2014.
[34]. Allen JD, et al. A systematic review of measures used in studies of human papillomavirus (HPV)
vaccine acceptability. Vaccine. 2010; 28(24):4027–4037. [PubMed: 20412875]
[35]. South Central Partnership for Public Health. Regional Meeting in Carthage, NC. Cates, J., editor.
University of North Carolina at Chapel Hill; 2013.
[36]. Shadish, WR.; Cook, TD.; Campbell, DT. Experimental and Quasi-Experimental Designs for
Generalized Causal Inference (pp. 54–61, 77–78, 117). Houghton Mifflin Company; Boston:
2002. p. 623
Cates et al. Page 11























• We evaluated a social marketing intervention to stimulate HPV vaccination.
(77)
• We modeled change in vaccination rates in 9–13 year old boys using NC
registry data. (85)
• Probability of vaccination increased significantly in the intervention region. (81)
• HPV vaccination rates were highest in the 11–12 year old boys.(64)
• Social marketing can promote timely vaccination of preteen boys against HPV.
(77)
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Kaplan-Meier curves showing vaccination in intervention and control counties and the entire
state. [all 4 graphs included in one Figure]
(a): HPV vaccination in 9–13 year old boys by intervention
(b): HPV vaccination in 9–13 year old girls by intervention
(c): Meningococcal vaccination in 9–13 year old boys by intervention
(d): Tdap vaccination in 9–13 year old boys by intervention
Note: The horizontal axis covers the period from six months pre- to six months post-
intervention, with the vertical lines denoting the start and end of the intervention.
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Kaplan-Meier curves showing effect modification by age, race, and Vaccines For Children
(VFC) eligibility on the intervention effect.
(e): HPV vaccination in 9–13 year old boys by age & intervention
(f): HPV vaccination in 9–13 year old boys by race & intervention
(g): HPV vaccination in 9–13 year old boys by VFC eligibility & intervention
Note: The horizontal axis covers the period from six months pre- to six months post-
intervention, with the vertical lines denoting the start and end of the intervention.
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Table 1
Demographic characteristics and vaccination outcomes by intervention group and for all of North Carolina for
males ages 9–13
Intervention Counties (N=19,842) Control Counties (N=6,027) Entire State (N=176,590)
N % N % N %
Age (years)
9–10 2,964 14.9 751 12.5 27,011 15.3
11–12 11,274 56.8 3,476 57.7 100,272 56.8
13 5,604 28.2 1,800 29.9 49,307 27.9
Race/Ethnicity
Non-Hispanic White 7,886 39.7 2,407 39.9 77,602 43.9
Non-Hispanic Black/AA 6,202 31.3 2,824 46.9 42,838 24.3
Hispanic 2,069 10.4 269 4.5 17,293 9.8
American Indian/Alaska Native 1,579 8.0 41 0.7 2,120 1.2
Other/Unknown Race 2,106 10.6 486 8.1 36,677 20.8
VFC Eligibility
Eligible for VFC dose 12,780 64.4 3,999 66.4 89,428 50.6
Ineligible 5,787 29.2 1,769 29.4 78,329 44.4
Eligibility unknown 1,275 6.4 259 4.3 8,833 5.0
Vaccination Status
6 mo. Pre-intervention 857 4.3 242 4.0 7,388 4.2
During intervention 1,458 7.3 314 5.2 11,426 6.5
6 mo. Post-intervention 1,356 6.8 395 6.6 11,902 6.7
Remained unvaccinated (censored) 16,171 81.5 5,076 84.2 145,874 82.6
Note: Data include all children aged 9–13 during the intervention who received either Tdap, meningococcal, or HPV vaccine by March 15, 2013.
Table 1 describes the males who had no record of receiving HPV vaccine prior to December 15, 2011, or 6 months before the start of the
intervention. Most participants in the “Other/Unknown race” category (>85%) were of unknown race. The remaining participants in that category
were described as American Indian/Alaska Native or Asian. A large number of 'unknown' race is due to this being a voluntary field for providers to
complete in the NCIR.
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Table 2
Cox proportional hazards models for time to vaccine initiation.
Intervention vs. control difference during
the intervention period relative to baseline
Intervention vs. control difference during
the post-intervention period relative to
baseline
Population Outcome Hazard ratio p-value Hazard ratio p-value
9–13 year old boys HPV initiation in boys 1.34 .002 .99 .88
Tdap booster .76 <.0001 .85 .02
Meningococcal vaccine .96 .59 .88 .12
9–13 year old girls HPV initiation 1.09 .32 .94 .48
Note: Models were adjusted for race, age, and VFC eligibility.
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Table 3
Effect modification (EM) of HPV initiation in boys, ages 9–13
Intervention effect during the intervention
Effect modifier Subgroup Hazard ratio p-value p-value for EM
Age 9–10 1.05 .72 <.0001
11–12 1.54 <.0001
13 1.09 .48
Race White 1.38 .0043 .08
Black/AA 1.41 .0019
Hispanic 1.09 .55
Eligibility for VFC dose VFC Eligible 1.30 .0072 .11
VFC Ineligible .0006
1.49
Note: Models were adjusted for race, age, and VFC eligibility.
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Table 4a
HPV series initiated in conjunction with receipt of Tdap and/or menmgococcal vaccine, boys ages 11–13
Number (%) receiving HPV vaccine/Number of opportunities† (%)
Entire State Intervention counties Control counties p-value for chi-square of interventionvs. control
6 mo. Pre-intervention 3788/17002 (22.3%) 484/1842 (26.3%) 114/510 (22.4%) 0.07
During intervention 6743/29183 (23.1%) 981/3313 (29.6%) 204/1085 (18.8%) <.0001
6 mo. Post-intervention 5779/20446 (28.3) 776/2392 (32.4%) 216/784 (27.6%) 0.01
†
An “opportunity” is defined as any administration of Tdap and/or meningococcal vaccine on a boy ages 11–13 who had not yet started the HPV
series.
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Table 4b
HPV series initiated in conjunction with receipt of meningococcal vaccine (but not Tdap), boys ages 11–13
Number (%) receiving HPV vaccine/Number of opportunities† (%)
Entire State Intervention counties Control counties p-value for chi-square of interventionvs. control
6 mo. Pre-intervention 1801/5758 (31.3%) 235/549 (42.8%) 55/154 (35.7%) p=.11
During intervention 2425/6706 (36.2%) 395/779 (50.7%) 75/216 (34.7%) p<.0001
6 mo. Post-intervention 3250/7855 (41.4%) 449/836 (53.7%) 117/258 (45.4%) p=.02
†
An “opportunity” is defined as any administration of meningococcal (but not Tdap) vaccine on a boy who had not yet started the HPV series
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